Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Nature Medicine2011Vol. 17(9), pp. 1094–1100
Citations Over TimeTop 1% of 2011 papers
Vinod P. Balachandran, Michael J. Cavnar, Shan Zeng, Zubin M. Bamboat, Lee M. Ocuin, Hebroon Obaid, Eric C. Sorenson, Rachel Popow, Charlotte E. Ariyan, Ferdinand Rossi, Peter Besmer, Tianhua Guo, Cristina R. Antonescu, Takahiro Taguchi, Jianda Yuan, Jedd D. Wolchok, James P. Allison, Ronald P. DeMatteo
Related Papers
- → Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients(2003)143 cited
- → Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors(2012)29 cited
- → Gastrointestinal Stromal Tumor (GIST) - Single Center Experience of prolonged treatment with Imatinib(2005)13 cited
- → Imatinib Dose Interruption in GIST: High Progression Risk for 3-YearResponders(2007)
- Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor(2014)